Shots:Amgen has reported the global P-III (VESALIUS-CV) trial findings assessing Repatha vs PBO, both in addition to optimized lipid-lowering therapy in adults (n >12,000) at high CV risk without prior heart attack or strokeAt an mFU of 4.5yrs., the trial met its co-1EPs of time to first occurrence of composite of coronary heart…
